Inovio Pharmaceuticals Inc (NASDAQ:INO)’s traded shares stood at 0.51 million during the last session, with the company’s beta value hitting 0.72. At the close of trading, the stock’s price was $4.17, to imply an increase of 3.73% or $0.15 in intraday trading. The INO share’s 52-week high remains $14.75, putting it -253.72% down since that peak but still an impressive 7.67% since price per share fell to its 52-week low of $3.85. The company has a valuation of $108.83M, with an average of 0.42 million shares in intraday trading volume over the past 10 days and average of 347.50K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Inovio Pharmaceuticals Inc (INO), translating to a mean rating of 2.00. Of 3 analyst(s) looking at the stock, 0 analyst(s) give INO a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 2 recommend it as a Buy.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Inovio Pharmaceuticals Inc (NASDAQ:INO) trade information
After registering a 3.73% upside in the last session, Inovio Pharmaceuticals Inc (INO) has traded red over the past five days. The 5-day price performance for the stock is -3.47%, and -26.46% over 30 days. With these gigs, the year-to-date price performance is -31.86%. Short interest in Inovio Pharmaceuticals Inc (NASDAQ:INO) saw shorts transact 3.5 million shares and set a 11.22 days time to cover.
The extremes give us $8 and $8 for target low and target high price respectively. As such, INO has been trading -91.85% off suggested target high and -91.85% from its likely low.
Inovio Pharmaceuticals Inc (INO) estimates and forecasts
Looking at statistics comparing Inovio Pharmaceuticals Inc share performance against respective industry, we note that the company has outperformed competitors. Inovio Pharmaceuticals Inc (INO) shares are -56.52% down over the last 6 months, with its year-to-date growth rate higher than industry average at 26.77% against 17.50%.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 13.49% for the past 5-year period. While 2024 is set for a 28.41% return in earnings, projections for the next 5 years are at 41.50% annually.
INO Dividends
Inovio Pharmaceuticals Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Inovio Pharmaceuticals Inc (NASDAQ:INO)’s Major holders
Inovio Pharmaceuticals Inc insiders hold 0.85% of total outstanding shares, with institutional holders owning 33.51% of the shares at 33.80% float percentage. In total, 33.51% institutions holds shares in the company, led by IFP ADVISORS, INC.
